Taxol Articles
NCI TO LICENSE AIDS DRUG CONOCURVONE
20 September 1993
HAUSER LOSES B-MS TAXOL CONTRACT
23 August 1993
PROTAXOLS OVERCOME TAXOL LIMITATIONS
16 August 1993
RHONE-POULENC: A TRANSFORMATION
16 August 1993
CYTOCLONAL GAINS FUNGAL TAXOL RIGHTS
16 August 1993
EISAI AND LILLY TEAM UP ON ANTIULCERANT
2 August 1993
SWEDEN LICENSES TAXOL
5 July 1993
HAUSER CHEMMICAL WINS NCI GRANTS
14 June 1993
PHASE II RESULTS WITH R-PR'S TAXOTERE
7 June 1993
RHONE-POULENC RORER'S FOCUSED R&D PIPELINE
7 June 1993
EDATREXATE COMBINATIONS IN CANCER
31 May 1993
ASCO STUDY SUPPORTS FIRST-LINE TAXOL
31 May 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
EHTNOBIOLOGY AND DRUG DEVELOPMENT
29 March 1993
IS GOVT GETTING ITS RESEARCH REWARDS?
8 March 1993
SANDOZ DEAL WITH SCRIPPS QUESTIONED
22 February 1993
US CRADAs AND INDUSTRY FEARS OF PRICE CONTROL
15 February 1993
SYNTHETIC TAXOL SOONER, SAYS B-MS
8 February 1993
ESCAGENETICS IN TAXOL LINK-UP
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
HAUSER DOUBLES TAXOL PRODUCTION
25 January 1993
B-M SQUIBB SETS US TAXOL PRICE
18 January 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
NEW CANCER DRUGS SHINE AT US MEETING
2 November 1992
US SCIENTISTS FIND ANTI-TOXIC AGENT
12 October 1992
B-MS NEW INDICATION
5 October 1992
RHONE-POULENC RORER REVIEWS DRUG PRIORITIES
5 October 1992
TAXOL APPROVED
3 August 1992
ITALIAN CO AIDS B-MS IN TAXOL SUPPLY
29 June 1992
NEW ANTICANCER AGENTS REPORTED
22 June 1992
MEETINGS DIARY FOR EUROPE
8 June 1992
TAXOL OF BENEFIT IN LUNG CANCER
1 June 1992
R-PR TO CODEVELOP TAXOTERE IN JAPAN
1 June 1992
TAXOL SYNTHESIS ADVANCE
27 April 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
